600196 复星医药
2025/06 - 中期
人民币(K¥)
2024/12
人民币(K¥)
2023/12
人民币(K¥)
2022/12
人民币(K¥)
2021/12
人民币(K¥)
经营活动产生之现金流量净额2,134,0004,476,9813,414,2174,217,5713,937,815
投资活动产生之现金流量净额(859,737)(3,613,323)(3,819,290)(4,064,038)(3,857,489)
筹资活动产生之现金流量净额(1,460,200)(1,002,586)(1,336,250)4,428,475(819,407)
汇率变动对现金及现金等价物的影响9,76327,98973,645128,342(134,712)
现金及现金等价物净增加/(减少)(176,174)(110,939)(1,667,678)4,710,350(873,794)
期初现金及现金等价物余额9,391,4509,502,38911,170,0676,459,7177,333,511
期末现金及现金等价物余额9,215,2769,391,4509,502,38911,170,0676,459,717